UK–US Arrangement — Relevance to Northern Ireland

The VPAG rebate is negotiated on behalf of all four UK nations. The reduction of the VPAG rebate from 22.9% to 14.5% therefore applies to NI as does the commitment to increase spending on innovative medicines from 0.3% to 0.6% of GDP. Northern Ireland endorses NICE technology appraisals through a separate DoH NI process. The […]

UK–US Arrangement — Relevance to Wales

The NICE threshold increase from April 2026 applies to NHS Wales, which follows NICE technology appraisals automatically. Nine additional medicines approved under the new threshold since April will require Blueteq forms to be created and activated for the Welsh deployment. The fast-track pilots announced by DHSC on 2 July are England-specific; AWMSG continues to assess […]